XNAS 06 Mar, 2026 2:30 PM (EST)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2026 | 745,875 | 745,875 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Strategy Ofcr | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2026 | 190,875 | 190,875 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2026 | 202,225 | 202,225 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2026 | 216,675 | 216,675 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2026 | 221,450 | 221,450 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2026 | 190,225 | 190,225 | - | - | Stock Option (Right to Buy) | |
| Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 09 Jan 2026 | 588,235 | 1,853,488 | - | 17 | 9,999,995 | Common Stock |
| David M. Goldstein | Chief Scientific Officer | 31 Dec 2025 | 1,000 | 0 | - | 0 | Common Stock | ||
| Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 8.95 per share. | 05 Dec 2025 | 64,969 | 1,143,845 | - | 9.0 | 581,473 | Common Stock |
| Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 10.73 per share. | 05 Dec 2025 | 51,380 | 1,265,253 | - | 10.7 | 551,307 | Common Stock |
| Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 10.01 per share. | 05 Dec 2025 | 70,028 | 1,213,873 | - | 10.0 | 700,980 | Common Stock |
| Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 7.75 per share. | 02 Dec 2025 | 100,000 | 1,012,849 | - | 7.8 | 775,000 | Common Stock |
| Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 8.18 per share. | 02 Dec 2025 | 66,027 | 1,078,876 | - | 8.2 | 540,101 | Common Stock |
| Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 7.55 per share. | 02 Dec 2025 | 96,000 | 912,849 | - | 7.6 | 724,800 | Common Stock |
| Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 7.46 per share. | 26 Nov 2025 | 86,350 | 816,849 | - | 7.5 | 644,171 | Common Stock |
| Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 7.64 per share. | 26 Nov 2025 | 38,702 | 730,499 | - | 7.6 | 295,683 | Common Stock |
| Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 7.64 per share. | 26 Nov 2025 | 48,537 | 691,797 | - | 7.6 | 370,823 | Common Stock |
| Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 7.20 per share. | 20 Nov 2025 | 125,743 | 643,260 | - | 7.2 | 905,350 | Common Stock |
| Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 6.05 per share. | 17 Nov 2025 | 102,652 | 379,745 | - | 6.1 | 621,045 | Common Stock |
| Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 6.56 per share. | 17 Nov 2025 | 137,772 | 517,517 | - | 6.6 | 903,784 | Common Stock |
| Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 5.51 per share. | 17 Nov 2025 | 914 | 277,093 | - | 5.5 | 5,036 | Common Stock |
| Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 5.25 per share. | 13 Nov 2025 | 276,179 | 276,179 | - | 5.3 | 1,449,940 | Common Stock |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jul 2025 | 49,800 | 49,800 | - | - | Stock Option (Right to Buy) | |
| Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jul 2025 | 49,800 | 49,800 | - | - | Stock Option (Right to Buy) | |
| Lynn A. Tetrault | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jul 2025 | 49,800 | 49,800 | - | - | Stock Option (Right to Buy) | |
| Sapna Srivastava | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jul 2025 | 49,800 | 49,800 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2025 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2025 | 662,000 | 662,000 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Strategy Ofcr | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2025 | 28,000 | 206,401 | - | 0 | Common Stock | |
| Roy Hardiman | Chief Business & Strategy Ofcr | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2025 | 111,950 | 111,950 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2025 | 111,950 | 111,950 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2025 | 28,000 | 28,000 | - | 0 | Common Stock | |
| David M. Goldstein | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2025 | 107,950 | 107,950 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2025 | 27,000 | 29,115 | - | 0 | Common Stock | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2025 | 101,850 | 101,850 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2025 | 25,450 | 28,450 | - | 0 | Common Stock | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2025 | 26,750 | 48,728 | - | 0 | Common Stock | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2025 | 107,100 | 107,100 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2025 | 42,800 | 42,800 | - | 0 | Common Stock | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2025 | 64,200 | 64,200 | - | - | Stock Option (Right to Buy) | |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 13,804 | 13,804 | - | - | Stock Option (Right to Buy) | |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 44,364 | 44,364 | - | - | Stock Option (Right to Buy) | |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 19,528 | 19,528 | - | - | Stock Option (Right to Buy) | |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 7,064 | 7,064 | - | - | Common Stock | |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 41,499 | 41,499 | - | - | Stock Option (Right to Buy) | |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 11,189 | 11,189 | - | - | Stock Option (Right to Buy) | |
| Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 1,214,582 | 4,801,370 | - | - | Common Stock | |
| Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 5.27 per share. | 02 May 2025 | 22,002 | 3,586,788 | - | 5.3 | 115,951 | Common Stock |
| Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 4.58 per share. | 02 May 2025 | 138,368 | 3,564,786 | - | 4.6 | 633,725 | Common Stock |
| Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 4.55 per share. | 02 May 2025 | 159,920 | 3,426,418 | - | 4.6 | 727,636 | Common Stock |
| Martin Babler | Director, President, CEO and Chairman | Purchase of securities on an exchange or from another person at price $ 6.44 per share. | 01 Apr 2025 | 15,650 | 106,454 | - | 6.4 | 100,733 | Common Stock |
| Alan B. Colowick | Director | Purchase of securities on an exchange or from another person at price $ 7.49 per share. | 01 Apr 2025 | 2,300 | 18,404 | - | 7.5 | 17,235 | Common Stock |
| Alan B. Colowick | Director | Purchase of securities on an exchange or from another person at price $ 6.97 per share. | 01 Apr 2025 | 16,104 | 16,104 | - | 7.0 | 112,309 | Common Stock |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 523,000 | 523,000 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Strategy Ofcr | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 180,000 | 180,000 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 180,000 | 180,000 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 180,000 | 180,000 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Srinivas Akkaraju | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 1,703,998 | 0 | - | - | Class A Common Stock | |
| Srinivas Akkaraju | Director | 01 Jul 2024 | 1,703,998 | 1,703,998 | - | - | Class A Common Stock | ||
| Srinivas Akkaraju | Director | 01 Jul 2024 | 1,703,998 | 0 | - | - | Series C Preferred Stock | ||
| Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 1,703,998 | 1,703,998 | - | - | Common Stock | |
| Roy Hardiman | Chief Business & Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 14,973 | 14,973 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Legal Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 30,642 | 0 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 30,642 | 30,642 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Legal Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 53,475 | 0 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 206,074 | 206,074 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Legal Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 206,074 | 0 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 53,475 | 53,475 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Legal Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 175,401 | 0 | - | - | Class A Common Stock | |
| Roy Hardiman | Chief Business & Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 175,401 | 175,401 | - | - | Common Stock | |
| Roy Hardiman | Chief Business & Legal Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 6,417 | 0 | - | - | Class A Common Stock | |
| Roy Hardiman | Chief Business & Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 6,417 | 6,417 | - | - | Common Stock | |
| Roy Hardiman | Chief Business & Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 42,780 | 42,780 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Legal Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 42,780 | 0 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Legal Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 151,871 | 0 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 151,871 | 151,871 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Legal Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 14,973 | 0 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 171,122 | 171,122 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 42,780 | 42,780 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 42,780 | 0 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 2,994 | 2,994 | - | - | Common Stock | |
| David M. Goldstein | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 2,994 | 0 | - | - | Class A Common Stock | |
| David M. Goldstein | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 213,903 | 213,903 | - | - | Common Stock | |
| David M. Goldstein | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 213,903 | 0 | - | - | Class A Common Stock | |
| David M. Goldstein | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 11,978 | 11,978 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 11,978 | 0 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 171,122 | 0 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 53,475 | 53,475 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 53,475 | 0 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 206,074 | 206,074 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 206,074 | 0 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 30,642 | 30,642 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 30,642 | 0 | - | - | Stock Option (Right to Buy) | |
| Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 01 Jul 2024 | 1,562,500 | 3,266,498 | - | 16 | 25,000,000 | Common Stock |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 38,000 | 38,000 | - | - | Stock Option (Right to Buy) | |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 38,000 | 38,000 | - | - | Stock Option (Right to Buy) | |
| Patrick C. Machado | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 38,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Sapna Srivastava | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 29,946 | 29,946 | - | - | Stock Option (Right to Buy) | |
| Sapna Srivastava | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 29,946 | 0 | - | - | Stock Option (Right to Buy) | |
| Sapna Srivastava | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 28,877 | 28,877 | - | - | Stock Option (Right to Buy) | |
| Sapna Srivastava | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 28,877 | 0 | - | - | Stock Option (Right to Buy) | |
| Sapna Srivastava | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 28,877 | 28,877 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 17,112 | 0 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 17,112 | 17,112 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 17,171 | 0 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 55,978 | 0 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 55,978 | 55,978 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 70,588 | 0 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 70,588 | 70,588 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 12,834 | 12,834 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 12,834 | 0 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 64,171 | 64,171 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 64,171 | 0 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 171,122 | 171,122 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 59,516 | 59,516 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 59,516 | 0 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 17,171 | 17,171 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 171,122 | 0 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 17,112 | 17,112 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 18,652 | 0 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 54,545 | 0 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 54,545 | 54,545 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 70,802 | 0 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 70,802 | 70,802 | - | - | Common Stock (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 64,171 | 0 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 64,171 | 64,171 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 5,347 | 0 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 5,347 | 5,347 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 85,561 | 0 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 85,561 | 85,561 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 171,122 | 0 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 171,122 | 171,122 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 12,834 | 0 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 12,834 | 12,834 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 18,652 | 18,652 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 5,347 | 5,347 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 3,208 | 3,208 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 3,208 | 0 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 3,208 | 3,208 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 34,224 | 0 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 34,224 | 34,224 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 19,251 | 0 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 19,251 | 19,251 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 10,695 | 0 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 10,695 | 10,695 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 3,208 | 0 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 3,208 | 3,208 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 4,663 | 0 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 4,663 | 4,663 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 9,161 | 0 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 9,161 | 9,161 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 21,390 | 0 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 21,390 | 21,390 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 29,946 | 0 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 29,946 | 29,946 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 534,759 | 534,759 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 534,759 | 0 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 106,951 | 106,951 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 106,951 | 0 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 380,852 | 380,852 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 380,852 | 0 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 21,390 | 21,390 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 21,390 | 0 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 21,390 | 21,390 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 90,804 | 90,804 | - | - | Common Stock | |
| Martin Babler | Director, President, CEO and Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 90,804 | 0 | - | - | Class A Common Stock | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 245,989 | 245,989 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 245,989 | 0 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 478,288 | 478,288 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 478,288 | 0 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 241,210 | 241,210 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 241,210 | 0 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 107,028 | 107,028 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 107,028 | 0 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 263,101 | 263,101 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 263,101 | 0 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 20,026 | 0 | - | - | Class A Common Stock | |
| Mark Bradley | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 21,978 | 0 | - | - | Class A Common Stock | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 21,978 | 21,978 | - | - | Common Stock | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 20,026 | 20,026 | - | - | Common Stock | |
| Mark Bradley | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 20,026 | 0 | - | - | Class A Common Stock | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 20,026 | 20,026 | - | - | Common Stock | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 4,278 | 4,278 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 4,278 | 0 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 4,278 | 4,278 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 130,481 | 0 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 130,481 | 130,481 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 128,342 | 0 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 128,342 | 128,342 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 12,834 | 0 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 12,834 | 12,834 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 23,093 | 0 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 23,093 | 23,093 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 155,304 | 0 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 155,304 | 155,304 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 53,475 | 0 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 53,475 | 53,475 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 73,155 | 73,155 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 42,780 | 0 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 42,780 | 42,780 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 21,390 | 0 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 21,390 | 21,390 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 11,842 | 0 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 11,842 | 11,842 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 79,572 | 0 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 79,572 | 79,572 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 38,502 | 0 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 38,502 | 38,502 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 33,796 | 0 | - | - | Class A Common Stock | |
| Sara Klein | General Counsel - Corp Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 33,796 | 33,796 | - | - | Common Stock | |
| Sara Klein | General Counsel - Corp Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 8,556 | 8,556 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 8,556 | 0 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 8,556 | 8,556 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 73,155 | 0 | - | - | Stock Option (Right to Buy) |